These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 32670175)
1. Epidemiology of Pediatric NMOSD in Germany and Austria. Lechner C; Breu M; Wendel EM; Kornek B; Schanda K; Baumann M; Reindl M; Rostásy K Front Neurol; 2020; 11():415. PubMed ID: 32670175 [No Abstract] [Full Text] [Related]
2. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. Kitley J; Waters P; Woodhall M; Leite MI; Murchison A; George J; Küker W; Chandratre S; Vincent A; Palace J JAMA Neurol; 2014 Mar; 71(3):276-83. PubMed ID: 24425068 [TBL] [Abstract][Full Text] [Related]
3. Neuromyelitis optica spectrum disorders with antibodies to myelin oligodendrocyte glycoprotein or aquaporin-4: Clinical and paraclinical characteristics in Algerian patients. Bouzar M; Daoudi S; Hattab S; Bouzar AA; Deiva K; Wildemann B; Reindl M; Jarius S J Neurol Sci; 2017 Oct; 381():240-244. PubMed ID: 28991690 [TBL] [Abstract][Full Text] [Related]
4. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Hor JY; Asgari N; Nakashima I; Broadley SA; Leite MI; Kissani N; Jacob A; Marignier R; Weinshenker BG; Paul F; Pittock SJ; Palace J; Wingerchuk DM; Behne JM; Yeaman MR; Fujihara K Front Neurol; 2020; 11():501. PubMed ID: 32670177 [TBL] [Abstract][Full Text] [Related]
6. The occurrence of myelin oligodendrocyte glycoprotein antibodies in aquaporin-4-antibody seronegative Neuromyelitis Optica Spectrum Disorder: A systematic review and meta-analysis. Li X; Zhang C; Jia D; Fan M; Li T; Tian DC; Liu Y; Shi FD Mult Scler Relat Disord; 2021 Aug; 53():103030. PubMed ID: 34118585 [TBL] [Abstract][Full Text] [Related]
8. Seroprevalence of MOG and AQP4 Antibodies and Outcomes in an Indian Cohort of Pediatric Acquired Demyelinating Syndromes. Sankhyan N; Rawat A; Vyas S; Sahu JK; Bhagwat C; Madaan P; Saini L; Saini AG; Suthar R; Sukhija J; Jayashree M Neuropediatrics; 2022 Oct; 53(5):351-357. PubMed ID: 35617966 [TBL] [Abstract][Full Text] [Related]
9. The clinical value of complement proteins in differentiating AQP4-IgG-positive from MOG-IgG-positive neuromyelitis optica spectrum disorders. Qin C; Chen B; Tao R; Chen M; Ma X; Shang K; Wu LJ; Wang W; Bu BT; Tian DS Mult Scler Relat Disord; 2019 Oct; 35():1-4. PubMed ID: 31276911 [TBL] [Abstract][Full Text] [Related]
10. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Kitley J; Woodhall M; Waters P; Leite MI; Devenney E; Craig J; Palace J; Vincent A Neurology; 2012 Sep; 79(12):1273-7. PubMed ID: 22914827 [TBL] [Abstract][Full Text] [Related]
11. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. van Pelt ED; Wong YY; Ketelslegers IA; Hamann D; Hintzen RQ Eur J Neurol; 2016 Mar; 23(3):580-7. PubMed ID: 26593750 [TBL] [Abstract][Full Text] [Related]
12. Anti-Argonaute antibodies as a potential biomarker in NMOSD. Carta S; Le Duy D; Rogemond V; Derache N; Chaumont H; Fromont A; Cabasson S; Boudot de la Motte M; Honnorat J; Marignier R J Neurol Neurosurg Psychiatry; 2023 Sep; 94(9):738-741. PubMed ID: 36810322 [TBL] [Abstract][Full Text] [Related]